Recent press releases

26 September 2006

Lectus Therapeutics Announces Relocation to
Cambridge, UK

Cambridge, UK 26 September 2006, Lectus Therapeutics Ltd (“Lectus”), the drug discovery and development company focusing on next-generation ion channel modulators, announced today the relocation of its corporate headquarters and research facility to the Babraham Research Campus, Cambridge, UK. Lectus, originally based in Bristol, UK, will run all research operations as well as commercial and financial activities from the new location.

Lectus’s relocation to Cambridge forms an important part of its strategy in developing a robust infrastructure to reflect the growth of its research and development activities following its successful £8.2m Series A financing announced earlier this year. Lectus has been operating part of its research activities at Babraham, since April 2006 following its acquisition of NeuroServe Limited, an electrophysiology company providing research facilities important in the development of Lectus’s ion channel modulators. Lectus has now taken steps to integrate its entire commercial and research activities, including the exploitation of its proprietary proteomics research engine, LEPTICS®, to the Cambridge biotechnology cluster.

Dr Roland Kozlowski, CEO of Lectus, commented: “Lectus’s move to the new facility at the Babraham Research Campus represents the next step in the implementation of our strategy for growth. With this move, we will benefit from improved research facilities and exceptional local infrastructure and will be in an excellent position to progress our next-generation ion channel drugs, for treatment of pain and urinary incontinence, towards the clinic.”

The address for Lectus’s new research and corporate facility is Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom. Full contact details can be found on www.lectustherapeutics.com.

 Download this press release

© Lectus Therapeutics Ltd. 2003–2010